Pregled bibliografske jedinice broj: 1070529
High doses of Δ9-tetrahydrocannabinol might impair irinotecan chemotherapy: A review of potentially harmful interactions
High doses of Δ9-tetrahydrocannabinol might impair irinotecan chemotherapy: A review of potentially harmful interactions // Clinical drug investigation, 40 (2020), 9; 775-787 doi:10.1007/s40261-020-00954-y (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1070529 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
High doses of Δ9-tetrahydrocannabinol might
impair irinotecan chemotherapy: A review of
potentially
harmful interactions
(High doses of Δ9-tetrahydrocannabinol might
impair irinotecan chemotherapy: A review of
potentially harmful interactions)
Autori
Kopjar, Nevenka ; Fuchs, Nino ; Brčić Karačonji, Irena ; Žunec, Suzana ; Katić, Anja ; Kozina, Goran ; Lucić Vrdoljak, Ana
Izvornik
Clinical drug investigation (1173-2563) 40
(2020), 9;
775-787
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Tetrahydrocannabinol ; irinotecan ; drug-drug interaction, illicit THC preparations
Sažetak
This review proposes the hypothesis that the effectiveness of irinotecan chemotherapy might be impaired by high doses of concomitantly administered Δ9-tetrahydrocannabinol (THC). The most important features shared by irinotecan and THC, which might represent sources of potentially harmful interactions are: first pass hepatic metabolism mediated by cytochrome P-450 (CYP) enzyme CYP3A4 ; glucuronidation mediated by uridine diphosphate glycosyltransferase (UGT) enzymes, isoforms 1A1 and 1A9 ; transport of parent compounds and their metabolites via canalicular ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 ; enterohepatic recirculation of both parent compounds which leads to an extended duration of their pharmacological effects ; possible competition for binding to albumin ; butyrylcholinesterase (BChE) inhibition by THC which might impair the conversion of parent irinotecan into the SN-38 metabolite ; mutual effects on mitochondrial dysfunction and induction of oxidative stress ; potentiation of hepatotoxicity ; potentiation of genotoxicity and cytogenetic effects leading to genome instability ; possible neurotoxicity ; and effects on bilirubin. The controversies associated with the use of highly concentrated THC preparations with irinotecan chemotherapy are also discussed. Despite all of the limitations, the body of evidence provided here could be considered relevant for human risk assessments and calls for concern in cases when irinotecan chemotherapy is accompanied by preparations rich in THC.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Farmacija
POVEZANOST RADA
Ustanove:
Institut za medicinska istraživanja i medicinu rada, Zagreb,
Klinički bolnički centar Zagreb,
Sveučilište Sjever, Koprivnica
Profili:
Ana Lucić Vrdoljak
(autor)
Nevenka Kopjar
(autor)
Irena Brčić Karačonji
(autor)
Goran Kozina
(autor)
Suzana Žunec
(autor)
Anja Katić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE